JAZZ
HealthcareJazz Pharmaceuticals plc
$174.39
+$1.24 (+0.72%)
Jan 5, 2026
Price History (1Y)
Analysis
Jazz Pharmaceuticals plc is a biotechnology company in the healthcare sector with a market capitalization of $10.60 billion and revenue of $4.16 billion (TTM). It has a significant scale with 2800 employees. The company's financial health shows mixed results. Its profitability is reflected in gross margins of 92.0% and operating margins of 22.3%. However, its net income (TTM) is -$368,484,000, resulting in a profit margin of -8.9%. On the other hand, its returns on equity and assets are -9.1% and 4.9%, respectively. The company's balance sheet shows $5.43 billion in debt and $2.05 billion in cash, with a current ratio of 1.65. The company's valuation context is reflected in a forward P/E of 7.71 and an EV/EBITDA of 8.65. It has experienced revenue growth of 6.7% (YoY) and earnings growth of 19.3% (YoY).
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Visit website →Key Statistics
- Market Cap
- $10.60B
- P/E Ratio
- N/A
- 52-Week High
- $182.99
- 52-Week Low
- $95.49
- Avg Volume
- 1.02M
- Beta
- 0.27
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- Ireland
- Employees
- 2,800